According to a recent report published by Future Market Insights, the global bartonellosis therapeutics market is slated to grow at a CAGR of 12% from 2023 to 2033, reaching a market value of US$ 3.72 Billion by the end of the said period of assessment. A robust product pipeline, in addition to upcoming launches, propelling the market growth. Growing R&D investments by major manufacturers for orphan-developing drugs and advanced product offerings are key market determinants. There were 791 prospective orphan drug applicants in clinical trials for the treatment of rare conditions in 2021.
The market for bartonellosis therapeutics is expected to grow over the forecast period because, without treatment, the mortality rate increase rapidly. Bartonellosis joins a dormant stage, accompanied by recurrence and the advancement of a chronic phase, the Peruvian wart, with the pathogen still present in the body. Antibiotic demand is rapidly increasing as a result of an increase in cat scratch disease cases and a surge in market growth.
For In-depth insights, Download Sample Copy@ https://www.futuremarketinsights.com/reports/sample/rep-gb-16416
According to World Bank data, the total population of the United Kingdom and France in 2021 were 67,326,569 and 67,499,343, respectively. The disease’s increased prevalence is compelling government bodies to spend on R&D approaches and fuel the development of breakthrough antibiotics therapy, as well as encouraging regulatory policies to accelerate the authorization and funding for research. BARDA, for example, has assisted several organizations in the development of novel treatments for bartonellosis in collaboration with the US government.
Key Takeaways from the Market Study
- The market for bartonellosis therapeutics is expected to be valued at US$ 1.2 Billion in 2023
- North America to generate major growth opportunities, with the U.S likely to grow at an 11.7% CAGR
- APAC to be yet another lucrative hotspot for investment, accounting for 33% of all treatments
- Europe to emerge as a significant player in the bartonellosis therapeutics domain, clocking a CAGR of 11.5%
- More than half of all bartonellosis conditions to be treated with antibiotics
- At least 2 out of 5 bartonellosis patients to prefer availing therapies in hospitals
“As bacterial infections become more prevalent, healthcare practitioners are devising highly advanced and effective therapeutic approaches. This is boding well for bartonellosis therapeutics, paving way for the introduction of a wide range of treatment alternatives,” says an FMI analyst
For critical insights on this market, request to ask an expert here@ https://www.futuremarketinsights.com/ask-question/rep-gb-16416
Key Market Players
Key players in the Bartonellosis Therapeutics market are Abbott, Allergan, Hoffmann-La Roche Ltd., GlaxoSmithKline plc, Merck Sharp & Dohme Corp., Novartis AG, Sanofi, Pfizer Inc., Teva Pharmaceutical Industries Ltd., Bayer AG, Viatris, Sun Pharmaceutical Industries Ltd., Lilly, Aurobindo Pharma, Lupin, AstraZeneca, Johnson & Johnson Private Limited, Boehringer Ingelheim International GmbH, Dr. Reddy’s Laboratories Ltd., Bristol-Myers Squibb Company.
- Bayer HealthCare Animal Health has been operating with veterinarians, physicians, and specialists on bartonellosis diseases all over the world. Also, Bayer Animal Health provides products such as Seresto, which protects pets from fleas and prevents bartonellosis. This is the latest in a series of innovative anti-parasite product lines from one of the world’s foremost animal medical companies.
- In July 2021, GlaxoSmithKline Plc. collaborated with Alector to develop and commercialize two clinical-stage, potential first in-class monoclonal antibodies named AL001 and AL101. These antibodies are designed to evaluate progranulin levels, a key regulator of immune activity in the brain assisting in managing neurodegenerative disorders.
Key Segments Profiled in the Bartonellosis Therapeutics Market Industry Survey
By Drug Class:
- Antibiotics
- NSAIDs
- Others
By Route of Administration:
- Oral
- Intravenous
- Others
By Distribution Channel:
- Hospital Pharmacy
- Retail Pharmacy
- Online Pharmacy
By End Users:
- Hospitals
- Clinics
- Others
Buy Complete Report@ https://www.futuremarketinsights.com/checkout/16416
About Future Market Insights, Inc.
Future Market Insights, Inc. is an ESOMAR-certified business consulting & market research firm, a member of the Greater New York Chamber of Commerce and is headquartered in Delaware, USA. A recipient of Clutch Leaders Award 2022 on account of high client score (4.9/5), we have been collaborating with global enterprises in their business transformation journey and helping them deliver on their business ambitions. 80% of the largest Forbes 1000 enterprises are our clients. We serve global clients across all leading & niche market segments across all major industries.
Contact:
Future Market Insights, Inc.
Christiana Corporate, 200 Continental Drive,
Suite 401, Newark, Delaware – 19713, USA
T: +1-845-579-5705
For Sales Enquiries: sales@futuremarketinsights.com
Browse All Reports: https://www.futuremarketinsights.com/reports
LinkedIn| Twitter| Blogs